Calcitonin receptor complexed with receptor activity-modifying protein (CTR–RAMP complex)

The **calcitonin receptor complexed with receptor activity-modifying proteins (RAMPs)** refers to a family of heterodimeric cell-surface receptors formed by the co-expression of the calcitonin receptor (CTR, a class B1 GPCR) with one of the RAMP isoforms (RAMP1, RAMP2, or RAMP3). RAMPs are single-transmembrane accessory proteins that regulate the trafficking, cell-surface expression, and ligand specificity of their GPCR partners. When CTR is expressed alone, it serves primarily as a receptor for the hormone calcitonin, crucial for bone and calcium homeostasis. When co-expressed with different RAMPs, CTR forms functional receptors for amylin or CGRP, producing amylin receptors (AMY1/2/3) with distinct pharmacology[2][4][5]. The RAMP-CTR complex is thus central to signaling pathways involved in bone metabolism, metabolic regulation, and neuropeptide action (notably migraine therapeutics). RAMPs modify the ligand-binding pocket and allosterically alter receptor conformation and signaling[2]. Drugs targeting these complexes act either as peptide mimetics (agonists such as pramlintide) or as antagonists (gepant class) and are being developed for various indications such as diabetes, osteoporosis, and migraine[5]. If greater specificity is needed (e.g., for a particular RAMP isoform and function, or distinguishing from calcitonin receptor-like receptor complexes), context must distinguish which isoform (CTR–RAMP1, CTR–RAMP2, or CTR–RAMP3) is under discussion, but collectively, "calcitonin receptor complexed with receptor activity-modifying proteins" refers to these GPCR-receptor assemblies involved in diverse physiological and disease processes[2][4][6].

Other names

Calcitonin receptor–RAMP complexAmylin receptor (depending on RAMP subtype, e.g., AMY1, AMY2, AMY3)CTR–RAMP1, CTR–RAMP2, CTR–RAMP3 complexes

Peptide or small-molecule agonists and antagonists bind to the receptor and modulate downstream signaling (primarily via Gs proteins/adenylyl cyclase activation, but also other pathways such as Ca2+, ERK, Akt)[5]. RAMP alters pharmacological specificity, trafficking, and ligand-binding profile of the calcitonin receptor[2][4].